These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Dysregulation of Escherichia coli α-hemolysin expression alters the course of acute and persistent urinary tract infection. Nagamatsu K; Hannan TJ; Guest RL; Kostakioti M; Hadjifrangiskou M; Binkley J; Dodson K; Raivio TL; Hultgren SJ Proc Natl Acad Sci U S A; 2015 Feb; 112(8):E871-80. PubMed ID: 25675528 [TBL] [Abstract][Full Text] [Related]
3. Metabolic Requirements of Escherichia coli in Intracellular Bacterial Communities during Urinary Tract Infection Pathogenesis. Conover MS; Hadjifrangiskou M; Palermo JJ; Hibbing ME; Dodson KW; Hultgren SJ mBio; 2016 Apr; 7(2):e00104-16. PubMed ID: 27073089 [TBL] [Abstract][Full Text] [Related]
4. Kinetics of uropathogenic Escherichia coli metapopulation movement during urinary tract infection. Walters MS; Lane MC; Vigil PD; Smith SN; Walk ST; Mobley HL mBio; 2012; 3(1):. PubMed ID: 22318320 [TBL] [Abstract][Full Text] [Related]
5. Adaptation of Arginine Synthesis among Uropathogenic Branches of the Escherichia coli Phylogeny Reveals Adjustment to the Urinary Tract Habitat. Hibbing ME; Dodson KW; Kalas V; Chen SL; Hultgren SJ mBio; 2020 Sep; 11(5):. PubMed ID: 32994329 [TBL] [Abstract][Full Text] [Related]
6. Dynamic persistence of UPEC intracellular bacterial communities in a human bladder-chip model of urinary tract infection. Sharma K; Dhar N; Thacker VV; Simonet TM; Signorino-Gelo F; Knott GW; McKinney JD Elife; 2021 Jul; 10():. PubMed ID: 34219648 [TBL] [Abstract][Full Text] [Related]
7. The glycobiology of uropathogenic E. coli infection: the sweet and bitter role of sugars in urinary tract immunity. Lupo F; Ingersoll MA; Pineda MA Immunology; 2021 Sep; 164(1):3-14. PubMed ID: 33763853 [TBL] [Abstract][Full Text] [Related]
8. The cytochrome bd-I respiratory oxidase augments survival of multidrug-resistant Escherichia coli during infection. Shepherd M; Achard ME; Idris A; Totsika M; Phan MD; Peters KM; Sarkar S; Ribeiro CA; Holyoake LV; Ladakis D; Ulett GC; Sweet MJ; Poole RK; McEwan AG; Schembri MA Sci Rep; 2016 Oct; 6():35285. PubMed ID: 27767067 [TBL] [Abstract][Full Text] [Related]
9. Flexible Metabolism and Suppression of Latent Enzymes Are Important for Alteri CJ; Himpsl SD; Shea AE; Mobley HLT J Bacteriol; 2019 Aug; 201(16):. PubMed ID: 31160397 [TBL] [Abstract][Full Text] [Related]
10. A non-canonical autophagy-dependent role of the ATG16L1 Wang C; Bauckman KA; Ross ASB; Symington JW; Ligon MM; Scholtes G; Kumar A; Chang HW; Twentyman J; Fashemi BE; Xavier RJ; Mysorekar IU Autophagy; 2019 Mar; 15(3):527-542. PubMed ID: 30335568 [TBL] [Abstract][Full Text] [Related]
11. Intracellular uropathogenic Escherichia coli are undetectable in urinary bladders after oral mecillinam treatment: An experimental study in a pig model of cystitis. Stærk K; Grønnemose RB; Palarasah Y; Lund L; Andersen TE Microb Pathog; 2022 Dec; 173(Pt A):105817. PubMed ID: 36244593 [TBL] [Abstract][Full Text] [Related]
12. The UbiI (VisC) Aerobic Ubiquinone Synthase Is Required for Expression of Type 1 Pili, Biofilm Formation, and Pathogenesis in Uropathogenic Escherichia coli. Floyd KA; Mitchell CA; Eberly AR; Colling SJ; Zhang EW; DePas W; Chapman MR; Conover M; Rogers BR; Hultgren SJ; Hadjifrangiskou M J Bacteriol; 2016 Oct; 198(19):2662-72. PubMed ID: 27161114 [TBL] [Abstract][Full Text] [Related]
14. Selection of Effective Antibiotics for Uropathogenic González MJ; Zunino P; Scavone P; Robino L Front Cell Infect Microbiol; 2020; 10():542755. PubMed ID: 33194792 [TBL] [Abstract][Full Text] [Related]
15. Host-Derived Nitric Oxide and Its Antibacterial Effects in the Urinary Tract. Svensson L; Poljakovic M; Demirel I; Sahlberg C; Persson K Adv Microb Physiol; 2018; 73():1-62. PubMed ID: 30262107 [TBL] [Abstract][Full Text] [Related]
16. Role of Hypoxia Inducible Factor-1α (HIF-1α) in Innate Defense against Uropathogenic Escherichia coli Infection. Lin AE; Beasley FC; Olson J; Keller N; Shalwitz RA; Hannan TJ; Hultgren SJ; Nizet V PLoS Pathog; 2015 Apr; 11(4):e1004818. PubMed ID: 25927232 [TBL] [Abstract][Full Text] [Related]
17. Virulence factors of uropathogenic E. coli and their interaction with the host. Lüthje P; Brauner A Adv Microb Physiol; 2014; 65():337-72. PubMed ID: 25476769 [TBL] [Abstract][Full Text] [Related]
18. CpxA Phosphatase Inhibitor Activates CpxRA and Is a Potential Treatment for Uropathogenic Escherichia coli in a Murine Model of Infection. Fortney KR; Smith SN; van Rensburg JJ; Brothwell JA; Gardner JJ; Katz BP; Ahsan N; Duerfeldt AS; Mobley HLT; Spinola SM Microbiol Spectr; 2022 Apr; 10(2):e0243021. PubMed ID: 35297652 [TBL] [Abstract][Full Text] [Related]
19. Intracellular lifestyles and immune evasion strategies of uropathogenic Escherichia coli. Hunstad DA; Justice SS Annu Rev Microbiol; 2010; 64():203-21. PubMed ID: 20825346 [TBL] [Abstract][Full Text] [Related]
20. Cytotoxic Necrotizing Factor-1 (CNF1) does not promote E. coli infection in a murine model of ascending pyelonephritis. Michaud JE; Kim KS; Harty W; Kasprenski M; Wang MH BMC Microbiol; 2017 May; 17(1):127. PubMed ID: 28545489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]